The CTI collaboration enables NIH and Pfizer scientists to identify biologic compounds with activity in a pathway or target of interest and move these compounds through laboratory testing and into clinical evaluation. NIH intramural researchers selected for CTI projects will have identified disease-related pathways or mechanisms as potential therapeutic targets that culminate in Phase I clinical trials to demonstrate proof-of-mechanism.
A cooperative research and development agreement (CRADA) collaboration with CTI includes, among other things, access to Pfizer's drug development expertise and publishing rights. Pfizer has the first right of refusal to exclusively license compounds and other intellectual property developed under the NIH-Pfizer CTI CRADA. However, research rights are not compromised by this collaboration. Should Pfizer decide not to move forward with a project, NIH still owns all the background intellectual property that it brought to the research program, and the investigator may continue his or her research independent of Pfizer’s CTI.
A joint NIH-Pfizer steering committee governs the collaboration and is responsible for selecting research projects and making decisions about the progress of those projects.
NIH’s intramural scientists can respond to CTI calls for proposals two times each year. Learn more about the current call for proposals and therapeutic areas of interest, or visit our frequently asked questions for more information.